Drugs / CD22 CAR-transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07328503 | Jun 2026 → Jan 2030 expected | B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD22 CAR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07328503 ↗ |
| Modality | Cell therapy | “The cells will be altered in a lab to create CD22 CAR T-cell therapy.” NCT07328503 ↗ |
| Route | Intravenous | “receive their modified T cells through a tube inserted into a vein” NCT07328503 ↗ |